By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Synthetic Biologics, Inc. 

3930 Varsity Drive

Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-332-7800 Fax: 734-332-7878


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Synthetic Biologics (SYN) Announces Completion Of Enrollment For Phase 2b Proof-Of-Concept Clinical Trial For SYN-004 (Ribaxamase) For The Prevention Of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea And The Emergence Of Antibiotic-Resistant Organisms 9/20/2016 6:58:44 AM
Synthetic Biologics (SYN) Reports Second Quarter 2016 Operational Highlights and Financial Results 8/4/2016 7:22:22 AM
Synthetic Biologics (SYN) Announces Completion Of End Of Phase 2 Meeting With FDA For SYN-010, Intended For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C) 8/2/2016 6:53:17 AM
Synthetic Biologics (SYN) To Report Second Quarter 2016 Operational Highlights And Financial Results On August 3, 2016 7/26/2016 6:47:25 AM
Synthetic Biologics (SYN) Announces Granting Of European And U.S. Composition Of Matter Patents For Ribaxamase 7/12/2016 6:46:05 AM
Synthetic Biologics (SYN) Receives USAN Approval For Generic Name Ribaxamase For Phase 2 Drug Candidate SYN-004 7/7/2016 7:33:52 AM
Synthetic Biologics (SYN) To Present At The 2nd Annual Cantor Fitzgerald Healthcare Conference 7/6/2016 6:57:45 AM
Synthetic Biologics (SYN) Announces Detailed Data From Two SYN-010 Phase 2 Clinical Trials For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C) 5/23/2016 9:21:37 AM
Synthetic Biologics (SYN) Announces Detailed Data From Two SYN-010 Phase 2 Clinical Trials For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C) 5/23/2016 5:59:53 AM
Synthetic Biologics (SYN) To Host Post-DDW 2016 Conference Call To Recap SYN-010 Phase 2 Clinical Trial Results For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C) 5/18/2016 8:36:31 AM
12345678910...
//-->